Jacobson Pharma Corporation Limited (2633.HK)

HKD 1.01

(0.0%)

EBITDA Summary of Jacobson Pharma Corporation Limited

  • Jacobson Pharma Corporation Limited's latest annual EBITDA in 2023 was 429.92 Million HKD , down -14.62% from previous year.
  • Jacobson Pharma Corporation Limited's latest quarterly EBITDA in 2023 FY was N/A , down -14.62% from previous quarter.
  • Jacobson Pharma Corporation Limited reported an annual EBITDA of 462.03 Million HKD in 2022, up 21.2% from previous year.
  • Jacobson Pharma Corporation Limited reported an annual EBITDA of 415.48 Million HKD in 2021, up 10.15% from previous year.
  • Jacobson Pharma Corporation Limited reported a quarterly EBITDA of 248.12 Million HKD for 2023 Q4, down 0.0% from previous quarter.
  • Jacobson Pharma Corporation Limited reported a quarterly EBITDA of 209.88 Million HKD for 2023 Q2, down 0.0% from previous quarter.

Annual EBITDA Chart of Jacobson Pharma Corporation Limited (2023 - 2013)

Historical Annual EBITDA of Jacobson Pharma Corporation Limited (2023 - 2013)

Year EBITDA EBITDA Growth
2023 429.92 Million HKD -14.62%
2022 462.03 Million HKD 21.2%
2021 415.48 Million HKD 10.15%
2020 377.2 Million HKD -18.3%
2019 484.48 Million HKD 2.98%
2018 448.34 Million HKD 15.12%
2017 409.66 Million HKD 16.84%
2016 317.22 Million HKD 26.58%
2015 263.32 Million HKD 36.96%
2014 191.78 Million HKD -6.6%
2013 266.91 Million HKD 0.0%

Peer EBITDA Comparison of Jacobson Pharma Corporation Limited

Name EBITDA EBITDA Difference
Pak Fah Yeow International Limited 150.4 Million HKD -185.852%
Grand Pharmaceutical Group Limited 2.96 Billion HKD 85.508%
Extrawell Pharmaceutical Holdings Limited -129.51 Million HKD 431.934%
Wai Yuen Tong Medicine Holdings Limited 113.79 Million HKD -277.793%
Qianhai Health Holdings Limited -50.22 Million HKD 955.922%
Lee's Pharmaceutical Holdings Limited 109.82 Million HKD -291.478%
Essex Bio-Technology Limited 418.37 Million HKD -2.759%
Tongfang Kontafarma Holdings Limited 76.63 Million HKD -461.013%
PuraPharm Corporation Limited -26.16 Million HKD 1742.864%
SSY Group Limited 2.11 Billion HKD 79.668%
JBM (Healthcare) Limited 204.39 Million HKD -110.343%
China Resources Pharmaceutical Group Limited 15.43 Billion HKD 97.214%